Skip to content
10-K

Annual Report

Arbutus Biopharma Corp ABUS

0001447028-26-000017

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 18, 2026 195.48M sh
Shares Diluted FY 2025 · Dec 31, 2025 191.6M sh
Shares Diluted FY 2025 · Dec 31, 2024 185.61M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $182K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$39.64M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$64.85M
Long Term Debt FY 2025 · Dec 31, 2025 $0
Short Term Investments FY 2025 · Dec 31, 2025 $73.46M
Short Term Investments FY 2025 · Dec 31, 2024 $86.29M
Cash And Equivalents FY 2025 · Dec 31, 2025 $18.01M
Cash And Equivalents FY 2025 · Dec 31, 2024 $36.33M
Stockholders Equity FY 2025 · Dec 31, 2025 $76.58M
Stockholders Equity FY 2025 · Dec 31, 2024 $97.37M
Stockholders Equity FY 2025 · Dec 31, 2023 $106.02M
Current Liabilities FY 2025 · Dec 31, 2025 $6.01M
Current Liabilities FY 2025 · Dec 31, 2024 $15.62M
Total Liabilities FY 2025 · Dec 31, 2025 $18.04M
Total Liabilities FY 2025 · Dec 31, 2024 $34.34M
Current Assets FY 2025 · Dec 31, 2025 $94.46M
Current Assets FY 2025 · Dec 31, 2024 $127.32M
Total Assets FY 2025 · Dec 31, 2025 $94.62M
Total Assets FY 2025 · Dec 31, 2024 $131.71M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.17
Eps Diluted FY 2025 · Dec 31, 2024 −$0.38
Eps Basic FY 2025 · Dec 31, 2025 −$0.17
Eps Basic FY 2025 · Dec 31, 2024 −$0.38
Sga Expense FY 2025 · Dec 31, 2025 $15.89M
Sga Expense FY 2025 · Dec 31, 2024 $22.11M
Rd Expense FY 2025 · Dec 31, 2025 $25.24M
Rd Expense FY 2025 · Dec 31, 2024 $54.04M
Net Income FY 2025 · Dec 31, 2025 −$33.5M
Net Income FY 2025 · Dec 31, 2024 −$69.92M
Operating Income FY 2025 · Dec 31, 2025 −$38.16M
Operating Income FY 2025 · Dec 31, 2024 −$76.32M
Revenue FY 2025 · Dec 31, 2025 $14.08M
Revenue FY 2025 · Dec 31, 2024 $6.17M